Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multi-virus specific cytotoxic T lymphocytes
- Development stage
- Unknown
- Lead developer
- Baylor College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Multi-virus specific cytotoxic T lymphocytes (multi-VSTs) are an adoptive cellular immunotherapy developed by Nissui Pharmaceutical (now Shimadzu Diagnostics) under an exclusive license from Baylor College of Medicine for the Japanese market. This therapy is designed to treat and prevent life-threatening opportunistic viral infections in immunocompromised patients, particularly those undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The product consists of donor-derived T cells that are expanded ex vivo and sensitized to antigens from five common viruses: Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Adenovirus (ADV), BK virus (BKV), and Human herpesvirus 6 (HHV-6). By infusing these multi-specific T cells, the patient's antiviral immunity is rapidly reconstituted, allowing for the targeted elimination of virus-infected cells while minimizing the risk of graft-versus-host disease (GvHD) typically associated with unmanipulated donor lymphocyte infusions.
- Other names
- multi-virus specific T-cellsmulti-VSTsVST therapymulti-virus specific T-cell therapy
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on multi-virus specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multi-virus specific cytotoxic T lymphocytes.